Uveal melanoma is a rare eye cancer that starts in the middle layer of the eye. People with uveal melanoma may notice blurry vision, new floaters, flashes of light, or a dark spot on the iris, and sometimes there are no early symptoms of uveal melanoma. It is usually a single tumor that develops in adulthood and can grow over time. Treatment often includes radiation plaques, proton beam therapy, or surgery, and doctors also monitor for spread to the liver and other organs. The outlook depends on tumor size and whether it has spread, but many people with uveal melanoma do well with prompt, specialized care.
Overview
Uveal melanomaSymptoms
Uveal melanoma often causes no symptoms at first. Early symptoms of uveal melanoma can include blurred or decreased vision, floaters or flashes, a dark spot on the iris, changing pupil shape, visual field loss, or, rarely, eye pain or redness.
Outlook and prognosis
Most people with uveal melanoma do well when it’s found early and treated promptly, with regular eye and liver checks over time. Risk of spread depends on tumor size, exact location in the eye, and specific tumor genetics. Ongoing follow‑up helps catch changes early and guide tailored care.
Causes and risk factors
Uveal melanoma stems from DNA changes in eye pigment cells. Risk is higher with light irises, fair skin, older age, northern European ancestry, ocular melanocytosis, and inherited variants like BAP1. UV light and arc welding may contribute, without eye protection.
Genetic influences
Genetics play a major role in uveal melanoma. Inherited risk is uncommon, but certain germline variants (like BAP1) increase risk. Within the tumor, chromosome 3 loss and gene changes (BAP1, SF3B1, EIF1AX) strongly influence prognosis and guide monitoring.
Diagnosis
Diagnosis of uveal melanoma starts with a dilated eye exam, then eye ultrasound and specialized imaging; biopsy is rarely needed. Blood tests and liver imaging (MRI or CT) help stage disease and look for spread.
Treatment and drugs
Treatment for uveal melanoma is tailored to tumor size, location, vision needs, and overall health. Options include plaque brachytherapy (targeted radiation), proton/charged‑particle therapy, or surgery (local resection or enucleation), with careful eye‑saving approaches when possible. For spread disease, systemic therapies—immunotherapy, targeted drugs like tebentafusp (for HLA‑A*02:01), and clinical trials—are considered alongside close liver monitoring.
Symptoms
Uveal melanoma can affect how you see, often in just one eye, and sometimes the changes are easy to overlook. Early symptoms of uveal melanoma can be subtle or absent, so many cases are found during a routine eye exam. Symptoms vary from person to person and can change over time. When symptoms do show up, they usually involve vision changes, eye appearance, or discomfort.
Things can look smudged, wavy, or out of focus, usually in one eye. You may struggle with small print or crisp details. This is one of the more common changes in uveal melanoma.
You may see tiny spots, threads, or cobweb shapes drifting across your view. They stand out against bright backgrounds like a blue sky.
Brief flickers or streaks of light can appear in one eye. They may come and go, especially in dim or changing light.
A gray or dark curtain can slide over part of your vision. This can signal a problem at the back of the eye and needs prompt eye care.
How people usually first notice Uveal melanoma?
Many people first notice uveal melanoma when one eye doesn’t see quite right—blurred or dim vision, a new blind spot, wavy lines, or flashes of light—especially if glasses or rest don’t fix it. Some notice a dark spot on the colored part of the eye (the iris) or a change in pupil shape, while others only learn of it during a routine eye exam when the doctor sees a pigmented mass inside the eye. These first signs of uveal melanoma can be subtle, so any new, persistent vision change in one eye deserves a prompt dilated eye exam.
Types of Uveal melanoma
Uveal melanoma has several clinical variants based on where the tumor starts inside the eye. These variants can feel similar day to day but differ in how they affect vision, how they’re found, and how they’re treated. People may notice different sets of symptoms depending on their situation. When people search for types of uveal melanoma, they’re usually referring to these location-based variants.
Iris melanoma
Begins in the colored part of the eye and often grows slowly. It may show up as a new dark spot on the iris or a change in an existing freckle. Vision changes are less common early on.
Ciliary body melanoma
Starts behind the iris, so it can be hidden until it gets larger. People may notice blurred vision, a change in glasses prescription, or a visible bulge in the iris. It can raise eye pressure and lead to pain for some.
Choroidal melanoma
Arises in the layer at the back of the eye and is the most common variant. Blurred or distorted vision, new floaters, or flashes of light can appear as it affects the retina. Some have no symptoms and it’s found during a routine eye exam.
What genetics can tell you about symptoms
Certain inherited changes in BAP1, SF3B1, or EIF1AX genes can influence how uveal melanoma behaves—BAP1 variants often link to faster‑growing tumors and higher spread risk, while SF3B1 and EIF1AX changes tend to relate to slower, localized disease. People with a strong family history or a known BAP1 tumor predisposition syndrome may notice earlier onset or multiple related cancers, so genetics can shape both timing and aggressiveness.
Causes and risk factors
Risk factors for uveal melanoma include light eye color, fair skin, freckles, and older age. Certain eye findings, like a mole in the eye or increased eye pigmentation, also raise risk. Inherited factors matter too, and an inherited change in a gene called BAP1 or a family history can increase the chance of uveal melanoma. Sunlight and welding glare may contribute, but research is mixed, so wearing UV-blocking sunglasses is sensible. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t).
Environmental and biological risk factors
Uveal melanoma is a rare eye cancer that can affect reading, driving, and other everyday visual tasks. Doctors often group risks into internal (biological) and external (environmental). Understanding environmental and biological risk factors for uveal melanoma can help you and your care team focus on what’s most relevant for monitoring. Below are key factors linked with higher risk.
Blue or green irises have less protective pigment in the uvea. This lower pigment level is linked with a higher chance of uveal melanoma. The pattern has been observed in multiple studies.
People with lighter skin have less melanin overall. Lower pigment is associated with higher uveal melanoma risk. This link appears even after accounting for other traits.
Risk increases with advancing age. Most uveal melanoma diagnoses occur in older adults.
Men have a slightly higher rate of uveal melanoma than women. The difference is small but consistent across studies.
Genetic risk factors
Genes can influence who develops uveal melanoma and how the tumor behaves. Most cases start when eye cells acquire specific DNA changes, while a smaller share arise in people with inherited predispositions. Carrying a genetic change doesn’t guarantee the condition will appear. If you’re wondering about inherited risk of uveal melanoma, genetic counseling can help clarify which tests, if any, make sense.
GNAQ/GNA11 drivers: Acquired changes in GNAQ or GNA11 switch on growth signals in most uveal melanomas. These tumor changes are not inherited or passed to children. They explain how the cancer starts in many cases.
Tumor BAP1 loss: When the tumor loses BAP1 function, it is more likely to spread to other organs. This is a genetic feature of the cancer cells, not something you are born with. Doctors may test the tumor to guide follow-up plans.
SF3B1 tumor changes: Some tumors carry SF3B1 changes linked to a risk of later metastasis. These are acquired in the eye tissue and are not inherited. They can refine prognosis in uveal melanoma.
EIF1AX tumor changes: Tumors with EIF1AX changes tend to have a lower risk of spreading. This genetic change happens in the cancer cells, not the rest of the body. It can inform surveillance for uveal melanoma.
Other driver genes: Less often, changes in CYSLTR2 or PLCB4 can start uveal melanoma. These are acquired in the eye and are not inherited. Testing can help identify the driver pathway.
BAP1 syndrome: An inherited change in the BAP1 gene greatly raises the chance of uveal melanoma and some other cancers. Families may notice cases at younger ages or in more than one relative. Genetic counseling and testing can confirm this risk.
MBD4 deficiency: Rare inherited changes in MBD4 can lead to early-onset uveal melanoma and sometimes blood cancers. This syndrome is uncommon but important to recognize in families with multiple cases. Testing guides screening for relatives.
Family history: Having close relatives with uveal melanoma suggests shared genetic risk. Most families will not have a single known gene, but a genetics team can review patterns. This can help decide if testing is appropriate.
Light eye color: Blue or green irises are linked to a higher chance of uveal melanoma compared with darker eyes. Eye color is inherited and reflects how pigment may protect inner eye tissues. Risk is still low for most people with light eyes.
European ancestry: People of European descent have a higher rate of uveal melanoma than other groups. This likely reflects inherited pigmentation patterns and other genetic factors. Risk is not destiny—it varies widely between individuals.
Lifestyle risk factors
Some day-to-day behaviors may shape exposure to light that reaches the eye’s internal tissues. Evidence is mixed, but several habits are linked to higher or lower odds in observational studies. Below are the lifestyle risk factors for uveal melanoma that are most often discussed in research.
Use of tanning beds can increase ocular UV/visible light exposure. Limiting or avoiding indoor tanning may reduce cumulative eye exposure.
Frequent, unprotected time outdoors during peak UV hours may raise eye light exposure. Seeking shade and planning activities outside peak UV times can lower exposure reaching the uveal tissues.
Skipping sunglasses or hats with brims lets more UV and high-energy visible light into the eye. Consistent use of UV-blocking eyewear can reduce the ocular dose that penetrates toward the uveal tract.
Arc welding emits intense light that can reach the eye if shields are not used properly. Adhering to welding eye-protection standards reduces high-intensity light exposure.
Risk prevention
You can’t fully prevent uveal melanoma, but you can lower risk and catch changes early. Some risks—like light eye color, fair skin, and age—aren’t changeable, so prevention focuses on smart protection and regular eye care. Prevention is about lowering risk, not eliminating it completely. Regular check-ups matter most if you’ve had high UV exposure, work with welding, or have a family history of related cancers.
Schedule comprehensive dilated eye exams every 1–2 years, or more often if you’re high risk. These visits can catch early symptoms of uveal melanoma, like new pigmented spots or subtle vision changes.
Wear wraparound sunglasses labeled UV400 and a wide-brimmed hat whenever you’re outdoors. This may reduce cumulative light exposure inside the eye, a low-cost step with little downside.
Skip indoor tanning, which delivers intense UV that can reach the eyes even with brief exposure. Avoiding tanning beds may help protect against eye and skin damage linked to cancer risk.
If you weld or work near high-intensity light sources, use approved face shields and filters every time. Arc welding has been linked to higher uveal melanoma risk in some studies, so strict eye protection is important.
Transmission
Uveal melanoma is not contagious—you can’t catch it from someone, and it doesn’t spread through touch, air, or bodily fluids. Most uveal melanoma develops from new genetic changes that arise only in the eye’s pigment cells and are not the kind you pass to children. When people ask how uveal melanoma is inherited, the answer is that genetic transmission of uveal melanoma is uncommon; rarely, an inherited change in certain cancer‑risk genes can increase a family’s chance of developing it. If several close relatives have uveal melanoma or related cancers, a genetics professional can help review your family history and discuss whether testing is appropriate.
When to test your genes
Consider genetic testing if you have uveal melanoma diagnosed at a young age, multiple primary melanomas (eye or skin), or close relatives with uveal melanoma or related cancers. Testing also helps tailor surveillance for metastasis and guides screening for associated syndromes (e.g., BAP1 tumor predisposition). Ask your care team for referral to a genetic counselor.
Diagnosis
You might notice small changes in daily routines, like new floaters, brief flashes of light, or a dim patch off to the side of your vision. Doctors usually begin with a focused eye exam and simple, in-office imaging before deciding on any advanced tests. Some people have no symptoms and a routine check-up reveals a suspicious spot. Here’s how uveal melanoma is diagnosed in a stepwise way, and what those tests look for.
Your eye specialist asks about vision changes, eye pain, and any past eye issues. This helps narrow the most likely causes. Family and health history can offer useful clues.
The doctor uses drops to widen the pupil and closely examines the inside of the eye. They look for a raised, pigmented spot, orange pigment, or fluid under the retina. These clinical features can point toward uveal melanoma.
Color photos document the appearance and size of the lesion. Comparing images over time shows whether it’s growing. This helps track changes that support a diagnosis of uveal melanoma.
This painless scan shows detailed cross-sections of the retina. It can reveal fluid under the retina and how the mass affects nearby layers. The images help distinguish uveal melanoma from look-alike lesions.
Stages of Uveal melanoma
Changes in vision or a dark spot noticed during an eye exam can lead to staging tests. Early symptoms of uveal melanoma can be subtle, and some people have no warning signs. Doctors stage the cancer by how large the tumor is inside the eye and whether it has spread beyond it. Different tests may be suggested to help clarify the stage before treatment decisions are made.
Stage I
The tumor is small and confined to the eye. Vision may be normal or only mildly affected.
Stage II
The tumor is larger or has features that raise concern but still remains within the eye. Visual symptoms may become more noticeable, like blurred vision or flashing lights.
Stage III
The tumor is large or has begun to grow just outside the eye into nearby tissues. Vision is often affected, and the risk of spread is higher.
Stage IV
The cancer has spread to distant organs, most often the liver and sometimes the lungs or bones. Symptoms can include tiredness, weight loss, or pain depending on where it has spread.
Outlook and prognosis
Many people ask, “What does this mean for my future?”, especially right after a diagnosis of uveal melanoma. The outlook is not the same for everyone, but most tumors caught early and treated while still confined to the eye can be managed with radiation or surgery, and many people keep good vision in at least one eye. When thinking about the future, it helps to know that risk is largely tied to whether cancer cells spread outside the eye, most often to the liver.
Doctors call this the prognosis—a medical word for likely outcomes. About half of people with uveal melanoma will never develop spread, even years later; for others, the cancer can appear in the liver or, less often, the lungs or bones, sometimes after a long quiet period. Early symptoms of uveal melanoma can be subtle or absent, which is why regular eye exams and close follow‑up after treatment matter. If metastasis occurs, survival varies by how much of the liver is involved, overall health, and how quickly treatment starts; some people live several years with modern, liver‑directed therapies and newer systemic treatments.
In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. Certain tumor features seen on biopsy or genetic testing (for example, chromosome changes or gene expression class) can refine individual risk, but not everyone with the same gene change will have the same outlook. Supportive care, monitoring liver health, and staying current with clinical trials can extend both length and quality of life. Talk with your doctor about what your personal outlook might look like, including your specific tumor markers, follow‑up schedule, and options if spread is ever suspected.
Long-term effects
Uveal melanoma can affect vision, overall health, and day-to-day life long after the initial treatment. Long-term effects vary widely, and they depend on tumor size, location in the eye, and whether the cancer spreads. Many people do well with focused eye treatment, while others face complications or later metastasis, most often to the liver. Regular follow-up is key to catch changes early and tailor care over time.
Blurry or distorted vision can persist or slowly worsen, especially after radiation or surgery. Some notice that early symptoms of uveal melanoma were subtle, like shadows or flashing lights. Reading, night driving, or depth perception may remain harder.
The cancer can spread years later, most commonly to the liver. This may cause no symptoms at first, then fatigue, abdominal discomfort, or abnormal liver tests. Survival and treatment choices often hinge on how early this spread is detected.
Radiation can lead to retinal damage, cataract, or dry, irritated eyes over time. These effects may appear months to years after therapy. Regular eye exams can help manage changes before they impair vision further.
Pressure inside the eye can rise due to the tumor or scarring from treatment. This can cause eye pain, halos, or gradual vision loss. Medicines, laser, or surgery may be needed to protect remaining vision.
How is it to live with Uveal melanoma?
Living with uveal melanoma often means moving through intense bursts of medical care—scans, eye exams, treatment decisions—followed by quieter stretches of watchful waiting. Vision changes can affect reading, driving, depth perception, or work tasks, and for some, treatment may lead to partial vision loss or removal of the eye; low-vision tools, orientation training, and thoughtful lighting can make daily life safer and easier. The emotional load—uncertainty about metastasis, frequent follow-ups, and adjusting to visible changes—can weigh on you and those close to you, but many find steadier ground with clear care plans, counseling, and peer support. Loved ones often become teammates in practical ways—rides to appointments, help with paperwork, and gentle checks on fatigue or mood—while learning to balance support with your independence.
Treatment and drugs
Treatment for uveal melanoma focuses on controlling the eye tumor, protecting vision when possible, and preventing spread. Options depend on tumor size, location, vision in the eye, and whether the cancer has reached other parts of the body. Many people are treated with eye-sparing radiation, such as plaque brachytherapy placed on the eye for a few days, or with proton/charged-particle beam therapy; smaller tumors may also be observed closely at first, while larger or vision-threatening tumors sometimes require surgery to remove part of the eye or, in some cases, the whole eye. If the cancer has spread, especially to the liver, doctors may use systemic treatments like immunotherapy or targeted drugs, and liver-directed therapies such as embolization or ablation; your doctor can help weigh the pros and cons of each option. Supportive care can make a real difference in how you feel day to day, and regular follow-up imaging of the liver and other organs is a key part of ongoing care.
Non-drug treatment
Care for uveal melanoma centers on local treatments to control the eye tumor and protect comfort and vision where possible. Non-drug treatments often lay the foundation for care, from precise radiation to surgeries and vision support. Options are tailored to tumor size, location, vision in each eye, and personal preferences. Follow-up is essential to track eye healing and overall health after treatment.
Careful monitoring with eye exams and imaging can be used for very small or uncertain lesions. This is often considered when found during checks for early symptoms of uveal melanoma. The plan changes if the spot grows or vision is threatened.
A tiny radioactive disc is sewn onto the outside of the eye over the tumor for several days to deliver focused radiation. This eye-sparing approach often controls the tumor while aiming to preserve vision. Side effects can include cataract or retinal changes over time.
Precisely targeted external radiation treats the tumor while limiting exposure to nearby healthy tissue. It is commonly used for tumors near delicate structures like the optic nerve. Vision can still decline depending on tumor size and location.
Heat-based laser (thermal) treatment may be added to radiation or used for select small tumors. It can shrink the tumor or seal feeding vessels. Not all tumors are suitable for laser.
Your genes may have an impact on how drugs work for you
Drugs for uveal melanoma can work differently based on inherited and tumor-specific gene changes, which affect how medicines are absorbed, broken down, and how cancer cells respond. Testing tumor genetics (like GNAQ/GNA11 or HLA status) can guide targeted choices and predict benefit from immunotherapy.
Pharmacological treatments
Drug therapy for uveal melanoma is most often used when the cancer has spread or can’t be removed, and choices depend on tumor features and overall health. Treatment options for metastatic uveal melanoma now include a few approved medicines and several specialized approaches aimed at liver metastases. Not everyone responds to the same medication in the same way. Your oncology team will match drugs to your HLA type, disease location (especially the liver), and your goals for control and quality of life.
For adults with HLA-A*02:01–positive unresectable or metastatic disease, this T‑cell–engaging drug has been shown to improve survival. It’s given by weekly infusion and commonly causes early fever and skin rash that are monitored and managed in clinic. HLA typing is required before use.
This immunotherapy combination can help some people when tebentafusp isn’t an option, though responses are less common than in skin melanoma. It carries a higher risk of immune side effects affecting organs like the bowel, liver, skin, or thyroid, so close monitoring is essential.
Single‑agent PD‑1 therapy is an option when combination immunotherapy isn’t suitable, with a lower rate of serious immune reactions. Benefits are modest for many, but some achieve disease control with fewer side effects.
Traditional chemotherapy may be used when other options aren’t available or effective. Response rates are generally low, and side effects like fatigue, low blood counts, and nausea are monitored and treated.
Genetic influences
After a uveal melanoma diagnosis, it’s common to wonder why it happened and what it means for your family. It’s natural to ask whether family history plays a role. Most uveal melanoma is not inherited; instead, gene changes arise only in the tumor itself, and doctors may test the tumor for changes in genes such as BAP1, SF3B1, or EIF1AX to estimate the risk of spread and plan follow-up. A smaller number of people carry an inherited change—most often in a gene called BAP1—that raises the chance of uveal melanoma along with cancers like mesothelioma, skin melanoma, or certain kidney tumors. Clues to an inherited cause include being diagnosed at a younger age, having several relatives with uveal melanoma, or a family history of those related cancers. Even when a hereditary change is present, it increases risk but doesn’t guarantee you’ll develop cancer. If any of these fit your story, your care team may suggest genetic counseling and genetic testing for uveal melanoma to clarify your risk and guide screening for you and close relatives.
Is Uveal melanoma genetic?
Genetics play a major role in uveal melanoma. Inherited risk is uncommon, but certain germline variants (like BAP1) increase risk. Within the tumor, chromosome 3 loss and gene changes (BAP1, SF3B1, EIF1AX) strongly influence prognosis and guide monitoring.
Pharmacogenetics—how genetics influence drug effects
In uveal melanoma, tumor genetics often shape which treatments are on the table and how well they may work. Alongside medical history and imaging, genetic testing of the tumor helps tailor care. For example, tebentafusp is an immune-based drug that helps some people only if they carry a specific tissue type called HLA‑A*02:01, so a simple blood test checks for this before starting. Results from genetic testing for uveal melanoma often show changes in GNAQ or GNA11 and in BAP1; while these don’t yet point to a single proven targeted pill, they can guide clinical trial choices and monitoring plans. Immune checkpoint medicines may still be used, but responses in uveal melanoma are generally lower than in skin melanoma, and researchers are studying whether tumor features such as BAP1 loss or gene expression class help identify who benefits. Here, genetics mainly means the tumor’s makeup rather than how your liver or enzymes metabolize a drug, though overall liver health and other medicines can still affect dosing and side effects.
Interactions with other conditions
Other eye and whole‑body conditions can influence how uveal melanoma is found and treated. Autoimmune illnesses may complicate the use of immunotherapy drugs (which activate your immune system to fight the cancer), and existing liver disease or hepatitis can affect both monitoring and treatment because uveal melanoma most often spreads to the liver. Diabetes and high blood pressure raise the risk of radiation-related eye damage after plaque or proton therapy, which can affect the macula or optic nerve and make vision changes more likely. Pre‑existing eye problems like glaucoma, cataracts, or age‑related macular degeneration can also blur or hide early symptoms of uveal melanoma, and they may shape which eye‑saving treatments are safest. A small number of people have an inherited BAP1 tumor‑predisposition syndrome; in these families, uveal melanoma can occur alongside mesothelioma, kidney cancer, or skin melanoma, so coordinated cancer screening is important. Ask if any medications for one condition might interfere with treatment for another.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described sudden changes in one eye—blurred patches, a shadow drifting across vision, or flashes of light—long before anyone could see the tumor hidden inside. Early doctors relied on light and simple lenses to peer through the pupil and sketch what they saw. Many living with uveal melanoma had no symptoms at first, so illness was often discovered only when sight dimmed or the eye’s shape began to change.
First described in the medical literature as a pigmented growth inside the eye, uveal melanoma was initially grouped with skin melanoma because both arise from pigment‑producing cells. Over time, descriptions became more precise as clinicians recognized it can start in different parts of the uvea—the iris at the front, the ciliary body, or the choroid at the back. Those locations shaped how it was found: iris tumors were sometimes spotted in a mirror; deeper choroidal tumors were noticed when straight lines on a page looked wavy or a corner of vision faded.
From early theories to modern research, the story of uveal melanoma tracks with advances in eye care. The ophthalmoscope in the 1800s allowed detailed drawings of tumor borders. In the mid‑1900s, ultrasound and dye studies helped doctors map size and blood flow without surgery. This changed treatment decisions, shifting from routine removal of the eye to vision‑sparing options for selected tumors.
In recent decades, awareness has grown as imaging sharpened. Optical coherence tomography, wide‑field photography, and enhanced ultrasound let specialists detect very small lesions and watch how they behave over time. Pathology also moved forward. Under the microscope, doctors learned that cell shape and growth patterns relate to risk. As medical science evolved, genetic testing of the tumor itself revealed changes in certain genes that act like dimmer switches on tumor behavior, helping predict the chance of spread.
Treatment history reflects this progress. Earlier approaches focused on removing the eye to control the disease. Later, radiation plaques, proton beam therapy, and targeted laser techniques allowed many to keep the eye while treating the tumor. At the same time, care teams developed structured follow‑up to watch the liver and other organs, since uveal melanoma most often spreads to the liver.
Not every early description was complete, yet together they built the foundation of today’s knowledge. Today, the history of uveal melanoma continues to influence care: careful eye exams catch early symptoms of uveal melanoma sooner, imaging guides safer treatments, and tumor profiling informs personalized follow‑up. Looking back helps explain why regular eye checks matter, even when vision seems fine, and why ongoing research aims to prevent spread and improve long‑term outcomes.